Adenovirus: Current epidemiology and emerging approaches to prevention and treatment

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Infections caused by adenoviruses are associated with significant morbidity and mortality in both hematopoietic stem cell and solid organ transplant recipients. The risk seems to be highest in allogeneic hematopoietic stem cell transplant recipients as well as heart, lung and small-bowel transplant recipients. Management of these infections may be difficult and includes reduction of immunosuppression whenever possible combined sometimes with antiviral therapy (mainly cidofovir). The currently available antiviral therapy is limited by the need for intravenous administration, potentially significant renal and hematologic toxicities. New emerging therapies such as brincidofovir and transfusion of adenovirus-specific T-lymphocytes may increase the available armamentarium for these potentially life-threatening infections.

Original languageEnglish (US)
Article number416
JournalCurrent Infectious Disease Reports
Volume16
Issue number8
DOIs
StatePublished - Aug 2014

Fingerprint

Adenoviridae
Epidemiology
Hematopoietic Stem Cells
Antiviral Agents
Transplants
Adenoviridae Infections
Infection
Intravenous Administration
Immunosuppression
Therapeutics
Morbidity
T-Lymphocytes
Kidney
Lung
Mortality
Transplant Recipients

Keywords

  • Adenovirus
  • Bone marrow transplant
  • Hematopoietic stem cell transplant
  • Solid organ transplantation

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Adenovirus : Current epidemiology and emerging approaches to prevention and treatment. / Sandkovsky, Uriel; Vargas, Luciano M; Florescu, Diana F.

In: Current Infectious Disease Reports, Vol. 16, No. 8, 416, 08.2014.

Research output: Contribution to journalArticle

@article{2b3940cf065e4d4abf71ab616d08c4b2,
title = "Adenovirus: Current epidemiology and emerging approaches to prevention and treatment",
abstract = "Infections caused by adenoviruses are associated with significant morbidity and mortality in both hematopoietic stem cell and solid organ transplant recipients. The risk seems to be highest in allogeneic hematopoietic stem cell transplant recipients as well as heart, lung and small-bowel transplant recipients. Management of these infections may be difficult and includes reduction of immunosuppression whenever possible combined sometimes with antiviral therapy (mainly cidofovir). The currently available antiviral therapy is limited by the need for intravenous administration, potentially significant renal and hematologic toxicities. New emerging therapies such as brincidofovir and transfusion of adenovirus-specific T-lymphocytes may increase the available armamentarium for these potentially life-threatening infections.",
keywords = "Adenovirus, Bone marrow transplant, Hematopoietic stem cell transplant, Solid organ transplantation",
author = "Uriel Sandkovsky and Vargas, {Luciano M} and Florescu, {Diana F}",
year = "2014",
month = "8",
doi = "10.1007/s11908-014-0416-y",
language = "English (US)",
volume = "16",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "8",

}

TY - JOUR

T1 - Adenovirus

T2 - Current epidemiology and emerging approaches to prevention and treatment

AU - Sandkovsky, Uriel

AU - Vargas, Luciano M

AU - Florescu, Diana F

PY - 2014/8

Y1 - 2014/8

N2 - Infections caused by adenoviruses are associated with significant morbidity and mortality in both hematopoietic stem cell and solid organ transplant recipients. The risk seems to be highest in allogeneic hematopoietic stem cell transplant recipients as well as heart, lung and small-bowel transplant recipients. Management of these infections may be difficult and includes reduction of immunosuppression whenever possible combined sometimes with antiviral therapy (mainly cidofovir). The currently available antiviral therapy is limited by the need for intravenous administration, potentially significant renal and hematologic toxicities. New emerging therapies such as brincidofovir and transfusion of adenovirus-specific T-lymphocytes may increase the available armamentarium for these potentially life-threatening infections.

AB - Infections caused by adenoviruses are associated with significant morbidity and mortality in both hematopoietic stem cell and solid organ transplant recipients. The risk seems to be highest in allogeneic hematopoietic stem cell transplant recipients as well as heart, lung and small-bowel transplant recipients. Management of these infections may be difficult and includes reduction of immunosuppression whenever possible combined sometimes with antiviral therapy (mainly cidofovir). The currently available antiviral therapy is limited by the need for intravenous administration, potentially significant renal and hematologic toxicities. New emerging therapies such as brincidofovir and transfusion of adenovirus-specific T-lymphocytes may increase the available armamentarium for these potentially life-threatening infections.

KW - Adenovirus

KW - Bone marrow transplant

KW - Hematopoietic stem cell transplant

KW - Solid organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=84901881172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901881172&partnerID=8YFLogxK

U2 - 10.1007/s11908-014-0416-y

DO - 10.1007/s11908-014-0416-y

M3 - Article

C2 - 24908344

AN - SCOPUS:84901881172

VL - 16

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 8

M1 - 416

ER -